Tags

Type your tag names separated by a space and hit enter

Prospective, randomized clinical trial of intravitreal triamcinolone treatment of neovascular age-related macular degeneration: one-year results.
Retina 2007 Nov-Dec; 27(9):1205-13R

Abstract

PURPOSE

To investigate the effect of intravitreal injection of high-dose (20-25 mg) triamcinolone acetonide on minimally classic or occult choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

METHODS

A prospective, double-masked, placebo-controlled, randomized clinical trial included 39 eyes with minimally classic or occult CNV secondary to AMD. The treatment group (21 eyes) received intravitreal injection (20-25 mg) of triamcinolone acetonide and the control group (18 eyes) received intravitreal injection (500 mug) of dexamethasone at 6-month intervals. Best-corrected ETDRS (Early Treatment Diabetic Retinopathy Study) score, contrast sensitivity score, and central macular volume were measured at 1 month, 3 months, 6 months, and 12 months.

RESULTS

Mean baseline best-corrected visual acuity (BCVA [logarithm of the minimal angle of resolution]) was 0.64 (Snellen equivalent, 20/80) in each group. At 1 month, 3 months, and 6 months after the injection, neither group had a significant change in BCVA. At 12 months, mean BCVA +/- SD significantly decreased to 1.06 +/- 0.34 (Snellen equivalent, 20/200) in the treatment group (paired t-test, P < 0.001), whereas it was 0.78 +/- 0.52 (Snellen equivalent, 20/125) in the control group (P = 0.23). The difference was marginally significant (P = 0.06, Student's t-test). All phakic eyes in the treatment group developed marked cataract progression.

CONCLUSIONS

Intravitreal injection of high-dose triamcinolone had no beneficial effect on eyes with minimally classic or occult CNV secondary to AMD and was associated with outcomes similar to those associated with intravitreal injection of dexamethasone, which was used as placebo.

Authors+Show Affiliations

Department of Ophthalmology, Ilsan Paik Hospital, College of Medicine, Inje University, Gyeonggido, Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

18046226

Citation

Lee, Jonghyun, et al. "Prospective, Randomized Clinical Trial of Intravitreal Triamcinolone Treatment of Neovascular Age-related Macular Degeneration: One-year Results." Retina (Philadelphia, Pa.), vol. 27, no. 9, 2007, pp. 1205-13.
Lee J, Freeman WR, Azen SP, et al. Prospective, randomized clinical trial of intravitreal triamcinolone treatment of neovascular age-related macular degeneration: one-year results. Retina (Philadelphia, Pa). 2007;27(9):1205-13.
Lee, J., Freeman, W. R., Azen, S. P., Chung, E. J., & Koh, H. J. (2007). Prospective, randomized clinical trial of intravitreal triamcinolone treatment of neovascular age-related macular degeneration: one-year results. Retina (Philadelphia, Pa.), 27(9), pp. 1205-13.
Lee J, et al. Prospective, Randomized Clinical Trial of Intravitreal Triamcinolone Treatment of Neovascular Age-related Macular Degeneration: One-year Results. Retina (Philadelphia, Pa). 2007;27(9):1205-13. PubMed PMID: 18046226.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prospective, randomized clinical trial of intravitreal triamcinolone treatment of neovascular age-related macular degeneration: one-year results. AU - Lee,Jonghyun, AU - Freeman,William R, AU - Azen,Stanley P, AU - Chung,Eun Jee, AU - Koh,Hyoung Jun, PY - 2007/11/30/pubmed PY - 2008/4/11/medline PY - 2007/11/30/entrez SP - 1205 EP - 13 JF - Retina (Philadelphia, Pa.) JO - Retina (Philadelphia, Pa.) VL - 27 IS - 9 N2 - PURPOSE: To investigate the effect of intravitreal injection of high-dose (20-25 mg) triamcinolone acetonide on minimally classic or occult choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). METHODS: A prospective, double-masked, placebo-controlled, randomized clinical trial included 39 eyes with minimally classic or occult CNV secondary to AMD. The treatment group (21 eyes) received intravitreal injection (20-25 mg) of triamcinolone acetonide and the control group (18 eyes) received intravitreal injection (500 mug) of dexamethasone at 6-month intervals. Best-corrected ETDRS (Early Treatment Diabetic Retinopathy Study) score, contrast sensitivity score, and central macular volume were measured at 1 month, 3 months, 6 months, and 12 months. RESULTS: Mean baseline best-corrected visual acuity (BCVA [logarithm of the minimal angle of resolution]) was 0.64 (Snellen equivalent, 20/80) in each group. At 1 month, 3 months, and 6 months after the injection, neither group had a significant change in BCVA. At 12 months, mean BCVA +/- SD significantly decreased to 1.06 +/- 0.34 (Snellen equivalent, 20/200) in the treatment group (paired t-test, P < 0.001), whereas it was 0.78 +/- 0.52 (Snellen equivalent, 20/125) in the control group (P = 0.23). The difference was marginally significant (P = 0.06, Student's t-test). All phakic eyes in the treatment group developed marked cataract progression. CONCLUSIONS: Intravitreal injection of high-dose triamcinolone had no beneficial effect on eyes with minimally classic or occult CNV secondary to AMD and was associated with outcomes similar to those associated with intravitreal injection of dexamethasone, which was used as placebo. SN - 0275-004X UR - https://www.unboundmedicine.com/medline/citation/18046226/Prospective_randomized_clinical_trial_of_intravitreal_triamcinolone_treatment_of_neovascular_age_related_macular_degeneration:_one_year_results_ L2 - http://Insights.ovid.com/pubmed?pmid=18046226 DB - PRIME DP - Unbound Medicine ER -